Answers are grounded in this paper and cite their sources.
INTRODUCTION: Dendrimers are highly branched, nanoscale molecules with precise architectures that enable controlled interactions with biological systems. Their tunable size, charge, and composition make them promising carriers for antiviral therapeutics. While dendrimer-based formulations have demonstrated efficacy against HIV, HSV, HPV, and SARS-CoV-2, applications in cytomegalovirus (CMV) therapy remain underexplored. Given CMV's clinical burden, particularly in immunocompromised patients and transplant recipients, there is a pressing need to optimize drug delivery strategies. AREAS COVERED: This review systematically evaluates dendrimer synthesis approaches, drug-loading techniques, and preclinical/clinical outcomes of dendrimer-based antiviral formulations. Relevant literature was identified through searches of PubMed, Scopus, ScienceDirect, Taylor & Francis Online, MDPI, and SpringerLink covering publications from January 2010 to August 2026. Special emphasis is placed on existing CMV therapeutics such as ganciclovir derivatives incorporated into dendrimer scaffolds. Evidence indicates that dendrimer conjugation enhances drug solubility, stability, and cellular uptake. Preliminary studies with ganciclovir-loaded dendrimers show improved antiviral activity and reduced systemic toxicity. However, no dendrimer-based formulations have yet advanced to late-stage CMV clinical trials. EXPERT OPINION: Expanding dendrimer applications to major anti-CMV drugs, including letermovir, maribavir, valganciclovir, foscarnet, and cidofovir, could enable targeted, sustained, and safer delivery. This review underscores dendrimers as structurally precise nanocarriers with transformative potential in CMV therapy, warranting further translational research.
No takes yet. Share an insight, caveat, or question.
Shetty et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: